Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US
Checked against the public recordLast updated Jun 17, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: nivolumab + ipilimumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * At least 18 years old at confirmed diagnosis with metastatic non-small cell lung cancer (NSCLC) (stage IV), squamous or non-squamous histology * Initiated first-line (1L) combination nivolumab, ipilimumab, and 2 cycles of platinum-doublet chemotherapy (NIC) regimen between 01 January 2018 and 2 years prior to study launch * Tumor programmed death-ligand 1 (PD-L1) negative expression (i.e., PD-L1 \<1%) * No EGFR, ALK, or ROS1 genetic mutation (i.e., wild type) * Minimum of 6 months of follow-up after initiation of 1L NIC\* Exclusion Criteria: • Any prior systemic therapy for metastatic non-small cell lung cancer (NSCLC)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cardinal HealthDublin, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 17, 2025. Always confirm current availability with the study team.